ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,614.56
-2.70%
Dow Jones
41,911.71
-2.08%
US Dollar vs MXN
20.3715
0.51%
Brent Oil
69.04
-0.98%
Bitcoin
79,327.91
-1.55%
Pepperstone
Advertisement
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Akebia Therapeutics Inc (AKBA) Cotización

Akebia Therapeutics Inc

Akebia Therapeutics Inc (AKBA)

NASDAQ
1.86
-0.04
(-2.11%)
Al cierre: 10 Marzo 2:00PM
Delayed by 15 minutes
1.8595
-0.0005
( -0.03% )
Fuera de horario: 3:52PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
1.8595
Postura de Compra
1.84
Postura de Venta
1.86
Volume Operado de la Acción
2,565,495
1.84 Rango del Día 1.91
0.80 Rango de 52 semanas 2.48
Capitalización de Mercado [m]
405.708M
Precio Anterior
1.90
Precio de Apertura
1.87
Hora
170
@
1.8595
(formt)
Última hora de negociación
16:52:01
Volumen financiero
US$ 4,805,335
Precio Promedio Ponderado
1.8731
Volumen promedio (3 m)
2,149,358
Acciones en circulación
218,181,202
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-7.86
Beneficio por acción (BPA)
-0.24
turnover
194.62M
Beneficio neto
-51.93M

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment... Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
www.akebia.com
Sede
Wilmington, Delaware, USA
Fundado
-
Akebia Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AKBA. The last closing price for Akebia Therapeutics was US$1.90. Over the last year, Akebia Therapeutics shares have traded in a share price range of US$ 0.80 to US$ 2.48.

Akebia Therapeutics currently has 218,181,202 shares in issue. The market capitalisation of Akebia Therapeutics is US$414.54 million. Akebia Therapeutics has a price to earnings ratio (PE ratio) of -7.86.

AKBA Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Marzo 2025
AKBA (-2.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Marzo 2025
AKBA (-2.11%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
03 Marzo 2025
AKBA (-2.11%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
03 Marzo 2025
AKBA (-2.11%)

Form 8-K - Current report
Edgar (US Regulatory)
07 Febrero 2025
AKBA (-2.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Febrero 2025
AKBA (-2.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Febrero 2025
AKBA (-2.11%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
04 Febrero 2025
AKBA (-2.11%)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.00950.5135135135141.851.961.7220884471.85556762CS
4-0.2805-13.10747663552.142.171.7220577761.89858987CS
120.02851.556526488261.8312.411.71521493581.98082519CS
260.434530.49122807021.4252.411.2419821211.84410246CS
520.339522.33552631581.522.480.829401831.58317972CS
156-0.9705-34.29328621912.832.860.24135361730.96882129CS
260-6.0005-76.34223918587.8613.780.24136986282.14328187CS

AKBA - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Akebia Therapeutics?
El precio actual de las acciones de Akebia Therapeutics es US$ 1.8595
¿Cuántas acciones de Akebia Therapeutics están en circulación?
Akebia Therapeutics tiene 218,181,202 acciones en circulación
¿Cuál es la capitalización de mercado de Akebia Therapeutics?
La capitalización de mercado de Akebia Therapeutics es USD 414.54M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Akebia Therapeutics?
Akebia Therapeutics ha negociado en un rango de US$ 0.80 a US$ 2.48 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Akebia Therapeutics?
El ratio precio/beneficio de Akebia Therapeutics es -7.86
¿Cuál es el ratio de efectivo a ventas de Akebia Therapeutics?
El ratio de efectivo a ventas de Akebia Therapeutics es 2.1
¿Cuál es la moneda de reporte de Akebia Therapeutics?
Akebia Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Akebia Therapeutics?
El último ingresos anual de Akebia Therapeutics es USD 194.62M
¿Cuál es el último beneficio anual de Akebia Therapeutics?
El último beneficio anual de Akebia Therapeutics es USD -51.93M
¿Cuál es la dirección registrada de Akebia Therapeutics?
La dirección registrada de Akebia Therapeutics es 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Akebia Therapeutics?
La dirección del sitio web de Akebia Therapeutics es www.akebia.com
¿En qué sector industrial opera Akebia Therapeutics?
Akebia Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
CUTRCutera Inc
US$ 0.185
(43.97%)
25.35M
TNONTenon Medical Inc
US$ 1.77
(41.60%)
3.54M
BKYIBIO key International Inc
US$ 1.38
(25.45%)
1.15M
SNOASonoma Pharmaceuticals Inc
US$ 3.40
(21.86%)
3.15M
LFMDLifeMD Inc
US$ 5.08
(18.97%)
273.06k
STSSSharps Technology Inc
US$ 0.3711
(-15.66%)
5.04M
MYPSPLAYSTUDIOS Inc
US$ 1.32
(-12.00%)
12.14k
BDRXBiodexa Pharmaceuticals PLC
US$ 2.51
(-11.93%)
135.47k
CAPSCapstone Holding Corp
US$ 2.74
(-11.90%)
3.61k
UALUnited Airlines Holdings Inc
US$ 68.90
(-11.23%)
825.52k
CUTRCutera Inc
US$ 0.18
(40.08%)
25.36M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 7.1699
(-2.85%)
8.13M
SYRSSyros Pharmaceuticals Inc
US$ 0.0992
(8.30%)
7.74M
NVDANVIDIA Corporation
US$ 105.5992
(-1.29%)
5.06M
STSSSharps Technology Inc
US$ 0.3711
(-15.66%)
5.04M

AKBA Discussion

Ver más
Monksdream Monksdream 2 días hace
AKBA under $2
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
AKBA test that 2.50 from a year ago
👍️0
TrendTrade2016 TrendTrade2016 2 meses hace
AKBA breaking out
👍️0
glenn1919 glenn1919 2 meses hace
AKBA....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 meses hace
akba........................https://stockcharts.com/h-sc/ui?s=akba&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 meses hace
AKBA.............................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 meses hace
AKBA.................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 3 meses hace
AKBA.....................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 4 meses hace
AKBA BIO BEAST INTO FDA
👍️0
TrendTrade2016 TrendTrade2016 4 meses hace
AKBA BEASTING LONG...FDA APPROVED DRUG COMES TO MARKET IN JAN
👍️0
TrendTrade2016 TrendTrade2016 4 meses hace
AKBA BUILDING 1.79 BREAK IS COMING
👍️0
TrendTrade2016 TrendTrade2016 5 meses hace
AKBA GAPPING AND READY FOR 1.79
👍️0
TrendTrade2016 TrendTrade2016 5 meses hace
AKBA BACK IN PLAY UNTIL JAN 2025...FDA COMING
👍️0
glenn1919 glenn1919 6 meses hace
AKBA.....................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 meses hace
AKBA................................https://stockcharts.com/h-sc/ui?s=ARKB&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 7 meses hace
AKBA......................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 8 meses hace
AKBA...........................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Krspecialized Krspecialized 8 meses hace
I believe the current news releases may have answered your question. GLTA
👍️0
Toofuzzy Toofuzzy 9 meses hace
Why do you say we have a gold mine here ?

Toofuzzy
👍️0
Krspecialized Krspecialized 9 meses hace
There's no doubt we have a gold mine here, and at some point it will be load up time. Figuring out when is the big question!
👍️0
eyeownu eyeownu 10 meses hace
SCARY MOVIE
👍️0
eyeownu eyeownu 10 meses hace
https://journey.ct.events/view/a825b116-e5ee-4e76-ad8d-2e9e9116aa21 tomorrows web cast
👍️0
eyeownu eyeownu 10 meses hace
added 2k@ 1.11
👍️ 1
glenn1919 glenn1919 10 meses hace
AKBA................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 11 meses hace
AKBA under $2

👍️0
eyeownu eyeownu 11 meses hace
ask is stacked! someone needs to slap it.
👍️0
eyeownu eyeownu 11 meses hace
$AKBA RELOAD
👍️0
Firestorm22 Firestorm22 11 meses hace
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
Firestorm22 Firestorm22 11 meses hace
Starting to remind me of a “pump and dump” stock. Spikes up but always comes back down to where it started.
👍️0
ErnieBilco ErnieBilco 11 meses hace
I'm in at 33 cents so I'm not going anywhere, just gonna let it ride wherever it goes
👍️ 1
Firestorm22 Firestorm22 11 meses hace
Thanks, I’m hanging onto it . With actual revenues of 40-60 mill the last 5 quarters, one would think this stock price should rise. I wouldn’t mind seeing them bought out.
👍️ 1
ErnieBilco ErnieBilco 11 meses hace
Classic sell the news. Probable offering coming next week to dilute on the good news.
👍️0
Firestorm22 Firestorm22 11 meses hace
Something just isnt right here. How do you get FDA approval for a drug and your stock price tank? Is there some bads news getting ready to come out on this company??
👍️0
Krspecialized Krspecialized 11 meses hace
Long solid position here!
👍️0
Limey42 Limey42 11 meses hace
Long term play. Congrats all!
👍️ 1
dugie100 dugie100 11 meses hace
Something didn’t look good , I guess!
👍️0
TrendTrade2016 TrendTrade2016 11 meses hace
AKBA should see 3 bucks
👍️0
TrendTrade2016 TrendTrade2016 11 meses hace
AKBA...FDA EXPLOSION ...WE LOADED THIS BEAUTY....KOCKED AND LOADED!!!!
👍️0
glenn1919 glenn1919 12 meses hace
AKBA...................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 12 meses hace
AKBA new 52 hi
👍️0
eyeownu eyeownu 12 meses hace
$AKBA looking good damn! she fine.
👍️ 1
glenn1919 glenn1919 12 meses hace
AKBA.................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 12 meses hace
$AKBA from stocktwits FDA’S THREE ALARM FIRE- (a)FDA issued CRL to FibroGen & Roxadustat (Aug. 2021); (b)FDA issued CRL to Akebia & Vadadustat (March 2022); (c)FDA’s Cardiovascular & Renal Drugs Advisory Committee supported GSK’s Daprodustat for dialysis dependent patients w/ anaemia of CKD w/ 13-3 vote (Oct. 2022); (d)Akebia submitted FDRR w/ FDA’s Senior Advisor in agency’s Office of New Drugs (OND) (Nov. 2022); (e)CKD community & key opinion leaders such as Dr. Jay Wish criticize FDA decision making concerning HIF-PHI drugs (March 2022 - present). (FDA knows from data that Daprodustat is inferior to Vadadustat.) FDA’S RESPONSE TO FIRE - (a)FDA met w/ Akebia to discuss appeal & subsequently requested “additional clarifying information” (not ADCOM, not clinical trial, not denial) (Nov. 2022); (b)FDA assigned Dr. Peter Stein, M.D., Director of OND as deciding authority for appeal (Feb. 2023); (c)Dr. Stein provided Akebia/Vadadustat w/ clear path forward to approval (May 2023). GLTA
👍️ 1
Monksdream Monksdream 1 año hace
AKBA 10Q March 4
👍️0
Tyrus603 Tyrus603 1 año hace
Excellent chart. Thank you for posting.

Found myself studying it for quite a bit.

As it really is a dream chart for both swing traders AND long term buy & hold investors alike.
👍️0
glenn1919 glenn1919 1 año hace
AKBA..............................................https://stockcharts.com/h-sc/ui?s=AKBA&p=W&b=5&g=0&id=p86431144783
👍️0
eyeownu eyeownu 1 año hace
$AKBA
👍️0
eyeownu eyeownu 1 año hace
$AKBA reversal incoming?
👍️0
eyeownu eyeownu 1 año hace
CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it has closed a loan facility with funds and accounts managed by BlackRock. The loan provides Akebia with up to $55.0 million of borrowing capacity available in three tranches.

At the closing, Akebia drew the first tranche of $37.0 million and used the proceeds to pay down $35.0 million of principal outstanding from a loan agreement with Pharmakon Advisors, LP (Pharmakon), the investment manager of the BioPharma Credit funds, plus interest and fees. The new agreement substantially extends the interest-only period in the event of vadadustat approval by the U.S. Food and Drug Administration (FDA) without requiring any principal repayment until December 31, 2025, with an option for Akebia to extend until December 31, 2026.
👍️0
eyeownu eyeownu 1 año hace
$AKBA profit taking! hope you took some off the table!
👍️0

Su Consulta Reciente

NASDAQ
AKBA
Akebia Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados

Quitar anuncios

Suscríbete a una experiencia sin publicidad

Sin anuncios

Pruébalo ahora

Mantenga los anuncios